Evidence from previous trials suggest that men receiving SRT benefit from the addition of ADT: RTOG 9601 showed an advantage in both, cancer-specific survival (CSS) and OS, for the use of 2 years bicalutamide (for all PSA values and for PSA > 1.5 ng/ml) and GETUG-AFU 16 showed an advantage in progression free survival and metastasis-free survival, for the use of 6 months Goserelin (39, 40). Here, KLK3 is linked to cancer.